Sign in

Private company

Codiak BioSciences, Inc.

American biological products company based in Cambridge, active since 20152

In its 2022 annual report the company says: “We are a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. We have utilized our engEx Platform to generate a deep pipeline of engineered exosomes, or engEx exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, infectious disease and rare disease.”46

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersCambridge, United States2
  • Incorporated inDE3
  • Business address35 Cambridgepark Drive, Suite 500, Cambridge, Ma 021403
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI549300QVVVW74Y10Q2302
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressCORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 57655432

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-303.2%Operating margin4
-162.0%Net margin4
686.8%Revenue growth, 20214
-69.4%Return on equity4
-$77.4MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development96¢$64.9M
  • Interest4¢$2.7M

Out of $22.9M in revenue.4 The company lost money this year.

Financial statements

Revenue54$22.9M in 2021+5811% since 2019
0$10.0M$20.0M$30.0M2019: $388.0K$388.0K20192020: $2.9M$2.9M2020+651%2021: $22.9M$22.9M2021+687%
Operating income54-$69.5M in 2021−13% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$80.2M-$80.2M20192020: -$90.9M-$90.9M2020+13%2021: -$69.5M-$69.5M2021−24%
Net income54-$37.2M in 2021−52% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$78.0M-$78.0M20192020: -$91.7M-$91.7M2020+18%2021: -$37.2M-$37.2M2021−59%
Fiscal year2018201920202021
Revenue$388.0K5$2.9M4$22.9M4
Research and development$59.5M5$74.0M4$64.9M4
Operating expenses$92.5M4
Operating income-$80.2M5-$90.9M4-$69.5M4
Interest$300.0K5$1.9M4$2.7M4
Income tax$05$04$04
Net income-$78.0M5-$91.7M4-$37.2M4

Compare Codiak BioSciences, Inc. with another company

Corporate structure

Codiak BioSciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Codiak BioSciences, Inc.

  • Codiak BioSciences, Inc. Cambridge, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Codiak BioSciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$35.3M4 Dec 31, 2021$41.9M4 Dec 31, 2020−15.8%
Accumulated depreciation$11.8M4 Dec 31, 2021$10.5M4 Dec 31, 2020+12.6%
Property and equipment, net$23.5M4 Dec 31, 2021$31.4M4 Dec 31, 2020−25.2%
Operating-lease assets (leased space)$22.0M4 Dec 31, 2021$22.0M4 Dec 31, 2020−0.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$76.9M4 Dec 31, 2021$88.9M4 Dec 31, 2020−13.5%
Debt securities available for sale$04 Dec 31, 2021$05 Dec 31, 2020

Leadership

Who has led Codiak BioSciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Douglas E. Williams2020–2023

President

  1. Douglas E. Williams2020–2023

Chief financial officer

  1. Linda Bain2020–2023
2025
Board members and other officers (19)

Timeline

  1. Mar 29, 20238-K Listing notice or transfer28
  2. Mar 27, 20238-K Bankruptcy or receivership; Exit or restructuring costs; Executive or director change29
  3. Nov 3, 20228-K Results of operations30
  4. Sep 14, 20228-K Entered a material agreement; Other events31
  5. Aug 30, 20228-K Exit or restructuring costs; Other events32
  6. Aug 4, 20228-K Results of operations33
  7. Jun 30, 20228-K Regulation FD disclosure34
  8. Jun 29, 20228-K Other events35
  9. Jun 21, 20228-K Shareholder vote36
  10. May 5, 20228-K Results of operations37
  11. Mar 10, 20228-K Results of operations38
  12. Nov 30, 20218-K Regulation FD disclosure39
  13. Oct 13, 2020New chief executive Douglas E. Williams becomes CEO8
  14. Jun 11, 2015Founded Codiak BioSciences, Inc. is founded2

Calendar

When it reported results

  1. Nov 3, 2022Reported quarterly or annual results30
  2. Aug 4, 2022Reported quarterly or annual results33
  3. May 5, 2022Reported quarterly or annual results37
  4. Mar 10, 2022Reported quarterly or annual results38
  5. Nov 4, 2021Reported quarterly or annual results40

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

110 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 18 major events, 68 insider forms, 9 large holders, 10 other. The latest 20:

  1. Feb 14, 2024SC 13G/A EDGAR
  2. Apr 10, 2023SC 13G/A EDGAR
  3. Mar 30, 20234 EDGAR
  4. Mar 30, 20234 EDGAR
  5. Mar 30, 20234 EDGAR
  6. Mar 30, 20234 EDGAR
  7. Mar 30, 20234 EDGAR
  8. Mar 30, 20234 EDGAR
  9. Mar 29, 2023NT 10-K EDGAR
  10. Mar 29, 20238-K EDGAR
  11. Mar 27, 20238-K EDGAR
  12. Mar 3, 2023SC 13G/A EDGAR
  13. Feb 21, 20234 FORM 4 SUBMISSION EDGAR
  14. Feb 21, 20234 FORM 4 SUBMISSION EDGAR
  15. Feb 21, 20234 FORM 4 SUBMISSION EDGAR
  16. Feb 21, 20234 FORM 4 SUBMISSION EDGAR
  17. Feb 21, 20234 FORM 4 SUBMISSION EDGAR
  18. Feb 21, 20234 FORM 4 SUBMISSION EDGAR
  19. Feb 21, 20234 FORM 4 SUBMISSION EDGAR
  20. Feb 21, 20234 FORM 4 SUBMISSION EDGAR

The 110 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

28 open-market trades by officers, directors and large owners since October 2021: 4 buys and 24 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 30, 2023Howze YalondaSee RemarksSale1,628$0.20$326Form 4
Mar 29, 2023Sathyanarayanan SriramChief Scientific OfficerSale11,762$0.17$2.0KForm 4
Mar 29, 2023Barna NicoleSee RemarksSale7,305$0.17$1.2KForm 4
Mar 28, 2023Konstantinov KonstantinChief Technology OfficerSale9,364$0.20$1.9KForm 4
Mar 28, 2023Bain LindaChief Financial OfficerSale13,412$0.17$2.3KForm 4
Mar 28, 2023WILLIAMS DOUGLAS EPresident & CEOSale41,667$0.18$7.5KForm 4
Feb 17, 2023Bain LindaChief Financial OfficerSale2,570$0.59$1.5KForm 4
Feb 17, 2023Konstantinov KonstantinChief Technology OfficerSale1,391$0.59$821Form 4
Feb 17, 2023WILLIAMS DOUGLAS EPresident & CEOSale7,681$0.59$4.5KForm 4
Feb 17, 2023Sathyanarayanan SriramChief Scientific OfficerSale2,407$0.59$1.4KForm 4
Feb 17, 2023Barna NicoleSee RemarksSale1,274$0.59$752Form 4
Feb 17, 2023Howze YalondaSee RemarksSale1,603$0.59$946Form 4
Jan 20, 2023Bain LindaChief Financial OfficerSale1,880$0.58$1.1KForm 4
Jan 20, 2023Konstantinov KonstantinChief Technology OfficerSale1,069$0.58$620Form 4
Jan 20, 2023Sathyanarayanan SriramChief Scientific OfficerSale1,082$0.58$628Form 4
Jan 20, 2023WILLIAMS DOUGLAS EPresident & CEOSale5,075$0.58$2.9KForm 4
Jan 20, 2023Howze YalondaSee RemarksSale1,512$0.58$877Form 4
Jan 20, 2023Barna NicoleSee RemarksSale836$0.58$485Form 4
Sep 15, 2022Flagship V VentureLabs Rx Fund, L.P.10% ownerBuy933,333Form 4
Sep 13, 2022GILLIS STEVENDirectorBuy5,000,000Form 4

All 28 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Codiak BioSciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCodiak BioSciences, Inc.1
  • CIK0001659352
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address35 Cambridgepark Drive, Suite 500, Cambridge, MA 021401
  • Phone617-949-41001
  • Shares outstanding36,829,626 as of Oct 27, 20227
  • Public float$412.7B as of Jun 30, 20214
  • On EDGAR sinceNov 25, 20151
  • Filings230 in all: 4 (103), 8-K (34), 3 (23), CORRESP (9), 10-Q (7), SC 13G/A (7), SC 13G (6), UPLOAD (5)1
    All 28 form types

    DRS (3), DRS/A (3), EFFECT (3), S-1 (3), S-8 (3), 10-K (2), 424B4 (2), 424B5 (2), D (2), DEF 14A (2), DEFA14A (2), 25-NSE (1), 8-A12B (1), CERT (1), NT 10-K (1), RW (1), S-1/A (1), S-1MEF (1), S-3 (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 10, 2022
    Quarterly report (10-Q) Nov 3, 2022
    Proxy statement (DEF 14A) Apr 29, 2022
    Latest 8-K (8-K) Mar 29, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46